Dublin, April 15, 2022 (GLOBE NEWSWIRE) -- The "Stem Cell Global Market Report 2022, By Source, By Product Type, By Application" report has been added to ResearchAndMarkets.com's offering.
The global stem cell market is forecast to grow from $11.59 billion in 2021 to $12.72 billion in 2022 at a compound annual growth rate (CAGR) of 9.8%. The market is expected to reach $18.51 billion in 2026 at a CAGR of 9.8%.
There is an increase in the prevalence of Chronic diseases worldwide which drives the Stem cell market. Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use. Currently, widely used stem cell treatment is the transplantation of blood stem cells to treat diseases and conditions of the blood and immune system, or to restore the blood system after treatments for specific cancers. According to WHO, in 2020, prevalence of chronic disease increased to 57%. As the prevalence of chronic disease increases, people opting for the stem cell-based treatment will rise, thus driving the market going forward. Currently, approximately 26,000 patients are treated with blood stem cells in Europe each year.
The low acceptance rate for stem cell therapy treatments is restraining the growth of the stem cell market. The acceptance rate is particularly low in the Embryonic stem cell therapeutics. Most of these stem cell therapies are yet to be proven in clinical trials and are highly experimental. Due to the nature of these unproven treatments, patients are reluctant to take up these therapies as they present serious health, personal and financial issues.
Companies in the stem cell therapeutics market are focusing on development of new technologies such as the Induced Pluripotent Stem Cells (IPSC) to boost the efficiency of stem cell therapies. IPSC are obtained from blood or skin cells that are reprogrammed to an embryonic-like pluripotent state by incorporating genes that are essential for maintaining key properties and growth of an unlimited source of any kind of human cell required for stem cell therapeutic purposes. These IPSC's are not derived from human embryos, which removes the bioethical issues, thus allowing scientists to obtain federal funding and support easily. A Japanese company, Oksara opened a medicine center that produced cells derived from iPS Cells. Similarly, Takar Bio company launched human iPSC derived Beta Cells i.e., Cellartis for disease modeling and drug discovery.
The Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) is the regulator in the US, for human cells, tissues, and cellular and tissue-based products (HCT/P) intended for implantation, transplantation, infusion or transfer into a human recipient, including hematopoietic stem cells. There are certain protocols that the FDA has established, for example, the current good tissue practice, donor screening and donor testing requirements which are in place to prevent the transmission of any communicable diseases. The stem cells come from different sources (bone marrow, umbilical cord blood or peripheral blood) and have different applications. Licenses are required to distribute and market these products.
Key Topics Covered:
1. Executive Summary
2. Stem Cell Market Characteristics
3. Stem Cell Market Trends And Strategies
4. Impact Of COVID-19 On Stem Cell
5. Stem Cell Market Size And Growth
5.1. Global Stem Cell Historic Market, 2016-2021, $ Billion
5.2. Global Stem Cell Forecast Market, 2021-2026F, 2031F, $ Billion
6. Stem Cell Market Segmentation
6.1. Global Stem Cell Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
6.2. Global Stem Cell Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
6.3. Global Stem Cell Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7. Stem Cell Market Regional And Country Analysis
7.1. Global Stem Cell Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Stem Cell Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8-26. Country and Regional Markets
27. Stem Cell Market Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Stem Cell Market
29. Stem Cell Market Future Outlook and Potential Analysis
Companies Mentioned
- Anterogen Co. Ltd
- Mesoblast Ltd.
- Osiris Therapeutics Inc.
- AlloSource
- Cellular Engineering Technologies
- BIOTIME Inc.
- Astellas Pharma US Inc.
- Vericel
- RTI Surgical Inc.
- Takara Bio Company
- BioTime Inc.
- Advanced Cell Technology
- MEDIPOST Co. Ltd
- JCR Pharmaceuticals Co. Ltd
- Holostem Terapie Avanzate S.r.l
- StemCells Inc.
- Regenexx
- Novartis
- Organogenesis
- Pharmicell Co.
- Caladrius Biosciences Inc.
- Athersys
- Geron Corporation
- Pluristem Therapeutics Inc.
- BrainStorm Cell Therapeutics Inc.
- Cryo Cell International
- Cytori Therapeutics Inc.
- U.S. Stem Cell Inc.
- Gilead
For more information about this report visit https://www.researchandmarkets.com/r/pzw8sj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
